SCHEMBL28237997

SCHEMBL28237997

C[C@@H](Cc1ccccc1)OC(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.50
TAAR1 Q96RJ0 2/20 0.50
SRR Q9GZT4 2/20 0.50
TSHR P16473 1/20 0.50
MAOA P21397 1/20 0.50
SLC6A4 P31645 1/20 0.50
SLC6A3 Q01959 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
EPHX1 P07099 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
CYP2A6 P11509 1/20 0.50
ADORA2A P29274 1/20 0.50
ADORA1 P30542 1/20 0.50
ALPI P09923 1/20 0.50
PKM P14618 1/20 0.50
PTGS1 P23219 1/20 0.50
XIAP P98170 1/20 0.50
SLC7A5 Q01650 1/20 0.50
CYP1A2 P05177 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1811694 1.00 SLC6A2 (0.50) SLC6A2TAAR1SRRTSHRMAOA
SCHEMBL28914994 1.00 SLC6A2 (0.50) SLC6A2TAAR1SRRTSHRMAOA
Methacrylic Acid SCHEMBL26100190 0.90 ALPI (0.46) SLC6A2TAAR1SRRTSHRMAOA
SCHEMBL114063 0.90 SRR (0.55) SRRTSHRPTGS1
SCHEMBL113258 0.85 PPARA (0.44) NPC1RAB9A
SCHEMBL28243883 0.85 PPARA (0.44) NPC1RAB9A
SCHEMBL2747604 0.85 TAAR1 (0.53) SLC6A2TAAR1TSHREPHX1SLC7A5
SCHEMBL2561209 0.85 NPC1 (0.45) TSHREPHX1NPC1RAB9APTGS1
SCHEMBL2747602 0.85 TAAR1 (0.53) SLC6A2TAAR1TSHREPHX1SLC7A5
SCHEMBL9136582 0.85 PPARG (0.44) TSHREPHX1NPC1RAB9ACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320178-A1 AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS NOVEN PHARMACEUTICALS, INC. (US) 2025-10-16 US disclosed
US-12365648-B2 Amphetamine carbamate compounds and methods NOVEN PHARMACEUTICALS, INC. (US) 2025-07-22 US disclosed
US-20240327337-A1 AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS NOVEN PHARMACEUTICALS, INC. (US) 2024-10-03 US disclosed
CN-115477634-B Analgesic compounds and medical uses thereof 中国人民解放军军事科学院军事医学研究院 2024-02-13 CN disclosed
CN-117529665-A Amphetamine carbamate compounds and methods 诺芬药品公司 2024-02-06 CN disclosed
CN-116997330-A Transdermal amphetamine compositions with low levels of carbamate 诺芬药品公司 2023-11-03 CN disclosed
CN-115477634-A Compound for analgesia and medical application thereof 中国人民解放军军事科学院军事医学研究院 2022-12-16 CN disclosed
CN-108472300-A Cyano thiophene and triazol diazacyclo heptantriene and application thereof 达纳-法伯癌症研究所股份有限公司 2018-08-31 CN disclosed
CN-108472299-A Acetamide thieno triazol diazacyclo heptantriene and application thereof 达纳-法伯癌症研究所股份有限公司 2018-08-31 CN disclosed
CN-108472295-A BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF 达纳-法伯癌症研究所股份有限公司 2018-08-31 CN disclosed
CN-108349924-A Benzenesulfonamido--benzofuran derivatives and application thereof 纪念斯隆凯特林癌症中心 2018-07-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327337-A1 AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS CHAT, CES2, NAAA SLC6A2 98/4885TAAR1 97/4885SRR 3464/4885
US-12365648-B2 Amphetamine carbamate compounds and methods CES2, CHAT, ACMSD SLC6A2 73/4885TAAR1 140/4885SRR 2128/4885
US-20250320178-A1 AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS CHAT, CES2, NAAA SLC6A2 98/4885TAAR1 97/4885SRR 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.